Policy & Regulation
Rexahn Pharmaceuticals signs collaboration and license agreement with Zhejiang Haichang Biotechnology
12 February 2018 -

United States-based Rexahn Pharmaceuticals has signed a collaboration and license agreement with China-based Zhejiang Haichang Biotechnology.

It was reported on Friday that the contract has been signed to develop RX-0201 (Archexin) intended for the treatment of hepatocellular carcinoma, the most common form of liver cancer.

According to the terms of the contract, Zhejiang Haichang Biotechnology will develop a nano-liposomal formulation of RX-0201 using its proprietary QTsome technology and conduct certain pre-clinical and clinical activities through completion of a Phase IIa proof-of-concept clinical trial for the treatment of hepatocellular carcinoma. Zhejiang Haichang Biotechnology will fund all research and development activities up to completion of the Phase IIa clinical trial. Both parties will share in an agreed ratio downstream licensing fees and royalties paid by third parties in connection with the further development and commercialisation of the nano-liposomal formulation of RX-0201 for the treatment of hepatocellular carcinoma.

Login
Username:

Password: